Nogo-B (7A12) Monoclonal Antibody
Applications
Reactivity
| Overview | |
| Catalog # | bsm-54117R |
| Product Name | Nogo-B (7A12) Monoclonal Antibody |
| Applications |
WB
FCM
IHC-P
IF(IHC-P)
IF(ICC)
|
| Reactivity | Human, Mouse |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | Recombinant protein within human Nogo aa 1-200 |
| Clonality | Monoclonal |
| Clone # | 7A12 |
| Isotype | IgG |
| Concentration | Lot Dependent |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at 4°C for up to 2 weeks. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Target | |
| Gene ID | 57142 |
| Swiss Prot | Q9NQC3 |
| Subcellular location | Endoplasmic reticulum |
| Synonyms | Reticulon-4B; RTN 4B; Foocen-M; RTN-xS; Neurite outgrowth inhibitor; Neuroendocrine-specific protein; Neuroendocrine-specific protein C homolog; |
| Background | Reticulon-4 is a developmental neurite growth regulatory factor with a role as a negative regulator of axon-axon adhesion and growth, and as a facilitator of neurite branching. It regulates neurite fasciculation, branching and extension in the developing nervous system. Reticulon-4 is also Involved in down-regulation of growth, stabilization of wiring and restriction of plasticity in the adult CNS. Isoform 2 of the Reticulon-4 protein, also known as Nogo-B or Reticulon-4B, reduces the anti-apoptotic activity of Bcl-xl and Bcl-2. This is likely consecutive to their change in subcellular location, from the mitochondria to the endoplasmic reticulum, after binding and sequestration. Isoform 2 (Nogo-B) and isoform 3 (Nogo-C) inhibit BACE1 activity and amyloid precursor protein processing. Nogo-B is mainly localized primarily in the endoplasmic reticulum (ER), where it participates in the maintenance of ER tubular shape and functions. Nogo-B is expressed in most tissues and is associated with diverse processes such as vascular remodeling, liver regeneration, liver cirrhosis, pulmonary hypertension, and inflammatory bowel disease. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |
| IHC-P | 1:200-400 |
| IF(IHC-P) | 1:50-200 |
| IF(ICC) | 1:50-200 |